667937-05-5

Basic information

• Product Name: 3-[4-(TRIFLUOROMETHYL)ANILINO]PENTANAMIDE
• Synonyms: (R)-3-[[4-(TrifluoroMethyl)phenyl]aMino]pentanaMide;3-[4-(TRIFLUOROMETHYL)ANILINO]PENTANAMIDE;(3R)-3-[(4-Trifluoromethylphenyl)amino]pentanamide
• CAS NO: 667937-05-5
• Molecular Formula: C₁₂H₁₅F₃N₂O
• Molecular Weight: 260.26
• Product Categories: Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 667937-05-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Solubility: Chloroform, Methanol
• CAS DataBase Reference: 3-[4-(TRIFLUOROMETHYL)ANILINO]PENTANAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-(TRIFLUOROMETHYL)ANILINO]PENTANAMIDE(667937-05-5)
• EPA Substance Registry System: 3-[4-(TRIFLUOROMETHYL)ANILINO]PENTANAMIDE(667937-05-5)

Safety Data

• Hazardous Substances Data: 667937-05-5(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Upstream product

• 198493-28-6 (R)-N-tert-butyloxycarbonyl-3-aminopentanenitrile 
• 400090-60-0 (R)-3-aminopentanenitrile 
• 98-56-6 4-chlorobenzotrifluoride 
• 474645-97-1 (R)-3-aminopentanenitrile methanesulfonic acid salt 
• 474645-90-4 (R)-3-[4-(trifluoromethyl)phenylamino]-pentanoic acid 
• 749921-33-3 3-(4-trifluoromethyl-phenylamino)-pentanoic acid methyl ester 

Downstream Products

• 474645-96-0 (2R,4S)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamic acid benzyl ester 
• 874501-92-5 C₂₆H₂₄F₉N₃O₂ 
• 874502-03-1 C₃₀H₃₁F₉N₆O₂ 
• 874501-96-9 C₂₈H₂₆F₉N₇O₂ 
• 874502-50-8 C₂₉H₂₈F₉N₇O₂ 
• 874502-29-1 C₂₈H₂₈ClF₉N₆O₂ 
• 874502-23-5 C₂₈H₂₉F₉N₆O₃ 
• 874502-05-3 C₂₉H₂₉F₉N₆O₄ 
• 874502-32-6 C₂₈H₂₈F₉N₇O₃ 
• 874502-35-9 C₃₀H₃₂F₉N₇O₃ 
• 874502-26-8 C₂₉H₃₁F₉N₆O₃ 
• 261947-57-3 [2R,4S]4-(3,5-bis-trifluoromethyl-benzylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester 
• 1380600-45-2 C₂₉H₂₉F₉N₄O₂ 
• 874501-94-7 C₂₆H₂₅F₉N₆O₂ 

Relevant articles and documents

Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors

Cholesteryl Ester Transfer Protein (CETP) is an important therapeutic target for the treatment of atherosclerotic cardiovascular disease. Our molecular modeling study revealed that pentacyclic triterpenoid compounds could mimic the protein-ligand interactions of the endogenous ligand cholesteryl ester (CE) by occupying its binding site. Alignment of the docking conformations of oleanolic acid (OA), ursolic acid (UA) and the crystal conformations of known CETP inhibitor Torcetrapib in the active site proposed the applicability of fragment-based drug design (FBDD) approaches in this study. Accordingly, a series of pentacyclic triterpenoid derivatives have been designed and synthesized as novel CETP inhibitors. The most potent compound 12e (IC50:0.28?μM) validated our strategy for molecular design. Molecular dynamics simulations illustrated that the more stable hydrogen bond interaction of the UA derivative 12e with Ser191 and stronger hydrophobic interactions with Val198, Phe463 than those of OA derivative 12b mainly led to their significantly different CETP inhibitory activity. These novel potent CETP inhibitors based on ursane-type scaffold should deserve further investigation.

Asymmetric synthesis of the cholesteryl ester transfer protein inhibitor torcetrapib

Previously our group reported synthetic efforts used to synthesize kilogram quantities of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, 1, via a mid-stage resolution. This account describes research conducted to develop an asymmetri

METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE

The present invention provides an industrially advantageous production method of optically active tetrahydroquinolines of formula (1), which comprises: 1) a step of reacting a β-ketoester of formula (2) with an amine of formula (3) to produce an enaminoester of formula (4); 2) a step of subjecting the enaminoester of formula (4) above obtained in 1) to asymmetric hydrogenation to produce an optically active β-amino acid derivative of formula (5); 3) a step of amidating the optically active β-amino acid derivative (5) above obtained in 2) to produce an amide of formula (6); 4) step of alkoxycarbonylating the amide of formula (6) above obtained in 3) to produce a compound of formula (7); and 5) a step of subjecting the compound of formula (7) above to cyclization to produce the optically active tetrahydroquinoline of formula (1).